Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

SZN-8141

Monoclonal antibody · developed by Surrozen Operating

Phase 1 Most advanced trial

SRZN Developer

1 Registered trials

What is SZN-8141?

SZN-8141 is a humanized antibody administered by intravitreal injection for diabetic macular edema.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Monoclonal antibody
Therapy area: Ophthalmology
Developer: Surrozen Operating, Inc. (SRZN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07817121	Phase 1	Diabetic Macular Edema (DME)	Not yet recruiting	SRZN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diabetic Macular Edema (DME)

Sources

ClinicalTrials.gov NCT07817121

Updated Oct 3, 2026. Something wrong or missing? Report it on the SRZN page.

Follow SRZN, the company behind SZN-8141

See SRZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SRZN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z